A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Public ClinicalTrials.gov record NCT01287741. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus rituximab (MabThera/Rituxan) with CHOP in previously untreated participants with cluster of differentiation 20 (CD20)-positive diffuse large B-cell lymphoma (DLBCL). Participants will be randomized to receive either obinutuzumab 1000 milligrams (mg) intravenously (IV) every 21 days or rituximab 375 milligrams per square meter (mg/m\^2) IV every 21 days for 8 cycles, in addition to 6-8 cycles of CHOP chemotherapy IV every 21 days. Participants randomized to the obinutuzumab arm will receive an additional two doses on Days 8 and 15 of Cycle 1. Anticipated time on study treatment is 24 weeks.
Study identification
- NCT ID
- NCT01287741
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,418 participants
Conditions and interventions
Conditions
Interventions
- Rituximab Drug
- Obinutuzumab Drug
- Cyclophosphamide Drug
- Doxorubicin Drug
- Vincristine Drug
- Prednisone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 26, 2011 (Actual)
- Primary completion
- Apr 29, 2016 (Actual)
- Completion
- Jan 31, 2018 (Actual)
- Last update posted
- Apr 12, 2019
2011 – 2018
United States locations
- U.S. sites
- 36
- U.S. states
- 18
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294-3300 | — |
| Ironwood Cancer TX & Rsch Ctrs | Chandler | Arizona | 85224 | — |
| Arizona Oncology | Tucson | Arizona | 85704 | — |
| California Cancer Associates for Research & Excellence, Inc. | Encinitas | California | 92008 | — |
| cCare | Encinitas | California | 92024 | — |
| UCLA - School of Medicine; Division of Hematology/Oncology | Los Angeles | California | 90095-6984 | — |
| Rocky Mountain Cancer Center - Aurora | Aurora | Colorado | 80012 | — |
| Florida Cancer Specialists; Department of Oncology | Fort Myers | Florida | 33901-8101 | — |
| Florida Cancer Specialists; Saint Petersburg | St. Petersburg | Florida | 33719 | — |
| Central Georgia Cancer Care PC | Macon | Georgia | 31201 | — |
| Illinois Cancer Care, P.C. - Galesburg | Galesburg | Illinois | 61401 | — |
| Joliet Oncology-Hematology; Associates, Ltd. | Joliet | Illinois | 60435 | — |
| Cancer Care & Hematology; Specialists of Chicagoland | Niles | Illinois | 60714 | — |
| Carle Cancer Center | Urbana | Illinois | 61801 | — |
| Mercy Oncology / Hematology Center; Oncology | Portland | Maine | 04102 | — |
| Park Nicollet Clin-Cancer Ctr | Saint Louis Park | Minnesota | 55426 | — |
| Minnesota Oncology Hematology Woodbury | Woodbury | Minnesota | 55125 | — |
| New York Oncology Hematology, P.C. | Albany | New York | 12206 | — |
| Mecklenburg Medical Group Charlotte | Charlotte | North Carolina | 28204 | — |
| Forsyth Regional Cancer Center; Piedmont Hematology/Oncology Associates | Winston-Salem | North Carolina | 27103 | — |
| Signal Point Clinical; Research Center, LLC | Middletown | Ohio | 45042 | — |
| Cleveland CL N Coast Cancer Cr | Sandusky | Ohio | 44870 | — |
| Willamette Valley Cancer Insitute and Research Center | Springfield | Oregon | 97477 | — |
| Medical University of SC (MUSC) | Charleston | South Carolina | 29425 | — |
| South Carolina Oncology Associates - SCRI | Columbia | South Carolina | 29210 | — |
| Chattanooga Oncology and Hematology Associates, PC | Chattanooga | Tennessee | 37404 | — |
| Tennessee Onc., PLLC - SCRI | Nashville | Tennessee | 37203 | — |
| Texas Oncology, Pa - Amarillo | Amarillo | Texas | 79106 | — |
| Texas Oncology-Fort Worth 12th Ave | Fort Worth | Texas | 76104 | — |
| MD Anderson Cancer Center Department of Lymphoma & Myeloma | Houston | Texas | 77030 | — |
| Cancer Care Centers of South Texas-HOAST - San Antonio | New Braunfels | Texas | 78130 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23226 | — |
| Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | — |
| Virginia Cancer Specialists - Winchester | Winchester | Virginia | 22601 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
| Wenatchee Valley Hospital & Clinics | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 199 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01287741, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2019 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01287741 live on ClinicalTrials.gov.